Dialysis-related amyloidosis: history and clinical manifestations.
Dialysis-related amyloidosis (DRA) or beta(2)-microglobulin amyloidosis (A beta(2)M) is a unique type of amyloidosis that has been described in individuals with both long-standing chronic renal disease and end-stage renal disease (ESRD). It has been associated with serious complications that significantly add to the morbidity of long-term dialysis patients. The deposition of beta(2)M in amyloid fibrils in various joint and osteoarticular surfaces leads to the clinical complaints and findings typical of this disorder. However, a visceral form with systemic organ involvement has also been described. Despite advances in the understanding of this disorder and in the delivery of dialysis, the ability to alter the incidence of DRA and its course remains uncertain.
Danesh
F
F
Division of Nephrology/Hypertension, Northwestern University Medical School, Chicago, Illinois 60611-3008, USA.
Ho
L T
LT
D000686:Amyloidosis / Q000209:etiology* / Q000378:metabolism; D001845:Bone Cysts / Q000209:etiology; D002349:Carpal Tunnel Syndrome / Q000209:etiology; D015775:Fractures, Stress / Q000209:etiology; D006801:Humans; D007592:Joint Diseases / Q000209:etiology; D006435:Renal Dialysis / Q000009:adverse effects*; D001613:beta 2-Microglobulin / Q000378:metabolism*
D001613:beta 2-Microglobulin